Treatment of refractory obesity with fenfluramine.
作者信息
Munro J F, Seaton D A, Duncan L J
出版信息
Br Med J. 1966 Sep 10;2(5514):624-5. doi: 10.1136/bmj.2.5514.624.
Abstract
摘要
相似文献
1
Treatment of refractory obesity with fenfluramine.用芬氟拉明治疗难治性肥胖症。
Br Med J. 1966 Sep 10;2(5514):624-5. doi: 10.1136/bmj.2.5514.624.
2
Comparison of a new anorectic agent AN 448 with fenfluramine in the treatment of refractory obesity.一种新型食欲抑制剂AN 448与芬氟拉明治疗难治性肥胖的比较。
Med J Aust. 1974 Jun 1;1(22):882-5. doi: 10.5694/j.1326-5377.1974.tb93399.x.
3
Fenfluramine in the treatment of obesity.
Lancet. 1973 Mar 10;1(7802):503-5. doi: 10.1016/s0140-6736(73)90325-5.
4
Toxic and therapeutic effects of EMTP in obesity.
Clin Pharmacol Ther. 1969 Jul-Aug;10(4):540-2. doi: 10.1002/cpt1969104540.
5
A collaborative investigation of fenfluramine. Anorexigenic with sedative properties.
Curr Ther Res Clin Exp. 1970 Aug;12(8):502-15.
6
A comparative trial of different regimens of fenfluramine and phentermine in obesity.
Practitioner. 1973 Aug;211(262):232-6.
7
Hypotensive effect of fenfluramine in the treatment of obesity.
Practitioner. 1971 Jul;207(237):101-5.
8
A clinical trial of fenfluramine.
Practitioner. 1965 Nov;195(169):677-80.
9
To the Editor: Fenfluramine (Poderax) for obesity.
S Afr Med J. 1969 Sep 27;43(39):1207.
10
[Experience with the appetite depressant, fenfluramine hydrochloride, in adiposity].
Med Klin. 1969;64(26):1201-7.
引用本文的文献
1
Efficacy of Low-Dose Fenfluramine on Adult Patients With Lennox-Gastaut Syndrome.低剂量芬氟拉明对患有伦诺克斯-加斯东综合征成年患者的疗效
Cureus. 2025 Jul 3;17(7):e87250. doi: 10.7759/cureus.87250. eCollection 2025 Jul.
2
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.用于治疗发育性和癫痫性脑病的已批准及新兴抗癫痫药物的药理学多样性。
Ther Adv Neurol Disord. 2023 Aug 30;16:17562864231191000. doi: 10.1177/17562864231191000. eCollection 2023.
3
Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy.芬氟拉明：癫痫药理学、临床疗效及安全性综述
Children (Basel). 2022 Aug 2;9(8):1159. doi: 10.3390/children9081159.
4
Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.芬氟拉明通过其对5-羟色胺5HT2A受体和1型σ受体的混合作用来减轻NMDA受体介导的癫痫发作。
Oncotarget. 2018 May 4;9(34):23373-23389. doi: 10.18632/oncotarget.25169.
5
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.低剂量芬氟拉明治疗神经系统疾病：在德雷维特综合征中的经验
Ther Adv Neurol Disord. 2015 Nov;8(6):328-38. doi: 10.1177/1756285615607726.
6
The usefulness of fenfluramine in treating simple obesity.芬氟拉明治疗单纯性肥胖的效用。
Can Fam Physician. 1972 Feb;18(2):55-7.
7
Comparison of continuous and intermittent anorectic therapy in obesity.肥胖症中持续和间歇性厌食疗法的比较。
Br Med J. 1968 Feb 10;1(5588):352-4. doi: 10.1136/bmj.1.5588.352.
8
The role of drugs in the treatment of obesity.
Drugs. 1981 May;21(5):362-73. doi: 10.2165/00003495-198121050-00004.
9
Effect of zimelidine, a new antidepressant, on appetite and body weight.新型抗抑郁药齐美利定对食欲和体重的影响。
Br J Clin Pharmacol. 1981 Jan;11(1):96-8. doi: 10.1111/j.1365-2125.1981.tb01112.x.
10
Fenfluramine.芬氟拉明
Br Med J. 1967 Jul 15;3(5558):159.
本文引用的文献
1
A PRELIMINARY TRIAL OF FENFLURAMINE IN GENERAL PRACTICE.氟苯丙胺在全科医疗中的初步试验
Br J Clin Pract. 1965 Aug;19:451-2.
2
CURRENT THERAPEUTICS. 203. SUSTAINED-ACTION CHLORPHENTERMINE IN THE CORRECTION OF REFRACTORY OBESITY.
Practitioner. 1964 Nov;193:698-702.
3
[PHARMACOLOGICAL COMPARISON OF 7 ANOREXIGENIC DRUGS].[7种食欲抑制药物的药理学比较]
Therapie. 1964 Jul-Aug;19:831-41.
4
Phenmetrazine hydrochloride and methylcellulose in the treatment of "refractory" obesity.盐酸芬美曲嗪与甲基纤维素治疗“难治性”肥胖症
Lancet. 1960 Jun 11;1(7137):1262-5. doi: 10.1016/s0140-6736(60)92249-2.
5
Diethyl-propion in the treatment of "refractory" obesity.二乙丙胺苯丙酮治疗“难治性”肥胖症。
Br Med J. 1961 Apr 8;1(5231):1009-11. doi: 10.1136/bmj.1.5231.1009.
6
A clinical trial of fenfluramine.
Practitioner. 1965 Nov;195(169):677-80.
Zotero 插件